Amplifying the Patient Voice: Reflections from MAPS EMEA 2025
At this year’s MAPS EMEA 2025 Annual Meeting in London, the message was clear: the patient voice is central to every stage of the drug development journey, a theme eloquently showcased in the Opening General Assembly: Patient Impact on Medical Affairs. Global leaders in Medical Affairs gathered to explore how the industry can evolve from…...
Read MoreTop Stories
What’s Next for Global Capability Centers )?
The theme for this year’s NASSCOM GCC Summit, “The Next GCC...
MAPS 2025 Decoded: The Medical Affairs Playbook
At the MAPS Americas 2025 conference in New Orleans, one of...
Medical Affairs 2.0: GenAI as the Catalyst for
Digital and AI were hot topics underpinning many of the...
Filter
Emerging Technologies: Healthcare Communication Friend or Foe?
Embracing emerging technologies and innovations is not just an option but a necessity for biopharma...
Periodic Safety Update Report (PSUR): A Breakdown of MDCG 2022-21
A well-structured, clear, and concise PSUR enables a seamless notified body review. Read our key...
Launch Excellence: The Path Forward for Medical Affairs
Learn how Medical Affairs can redefine launch excellence by streamlining the journey from clinical trial...
Clinical Evidence: How Much Is Enough?
Ensuring the safety and functionality of your medical device is vital. But how much clinical...
Medical Device Manufacturing: Risk-Based QMS Alignment for EU MDR
The latest EU-MDR guidelines are a step in the right direction, moving from a focus...
Why Do Plain Language Clinical Trial Summaries Matter?
Did you know that the European Medicines Agency’s Clinical Trials Regulation comes into effect on...